Cargando…
Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface
Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629431/ https://www.ncbi.nlm.nih.gov/pubmed/37930310 http://dx.doi.org/10.1080/19420862.2023.2273449 |
_version_ | 1785131965799727104 |
---|---|
author | Bagert, John D. Oganesyan, Vaheh Chiang, Chi-I Iannotti, Mike Lin, Jia Yang, Chunning Payne, Sterling McMahon, Will Edwards, Samuel Dippel, Andrew Hutchinson, Mark Huang, Fengying Aleti, Vineela Niu, Chendi Qian, Chen Denham, Jessica Ferreira, Sofia Pradhan, Pallab Penney, Mark Wang, Chunlei Liu, Wenhai Walseng, Even Mazor, Yariv |
author_facet | Bagert, John D. Oganesyan, Vaheh Chiang, Chi-I Iannotti, Mike Lin, Jia Yang, Chunning Payne, Sterling McMahon, Will Edwards, Samuel Dippel, Andrew Hutchinson, Mark Huang, Fengying Aleti, Vineela Niu, Chendi Qian, Chen Denham, Jessica Ferreira, Sofia Pradhan, Pallab Penney, Mark Wang, Chunlei Liu, Wenhai Walseng, Even Mazor, Yariv |
author_sort | Bagert, John D. |
collection | PubMed |
description | Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provide favorable pharmacology and pharmacokinetic profiles. The production of correctly assembled asymmetric monovalent bsIgGs, however, is a complex engineering endeavor due to the propensity for non-cognate heavy and light chains to mis-pair. Previously, we introduced the DuetMab platform as a general solution for the production of bsIgGs, which utilizes an engineered interchain disulfide bond in one of the C(H)1-C(L) domains to promote orthogonal chain pairing between heavy and light chains. While highly effective in promoting cognate heavy and light chain pairing, residual chain mispairing could be detected for specific combinations of Fv pairs. Here, we present enhancements to the DuetMab design that improve chain pairing and production through the introduction of novel electrostatic steering mutations at the C(H)1-C(L) interface with lambda light chains (C(H)1-C(λ)). These mutations work together with previously established charge-pair mutations at the C(H)1-C(L) interface with kappa light chains (C(H)1-C(κ)) and Fab disulfide engineering to promote cognate heavy and light chain pairing and enable the reliable production of bsIgGs. Importantly, these enhanced DuetMabs do not require engineering of the variable domains and are robust when applied to a panel of bsIgGs with diverse Fv sequences. We present a comprehensive biochemical, biophysical, and functional characterization of the resulting DuetMabs to demonstrate compatibility with industrial production benchmarks. Overall, this enhanced DuetMab platform substantially streamlines process development of these disruptive biotherapeutics. |
format | Online Article Text |
id | pubmed-10629431 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-106294312023-11-08 Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface Bagert, John D. Oganesyan, Vaheh Chiang, Chi-I Iannotti, Mike Lin, Jia Yang, Chunning Payne, Sterling McMahon, Will Edwards, Samuel Dippel, Andrew Hutchinson, Mark Huang, Fengying Aleti, Vineela Niu, Chendi Qian, Chen Denham, Jessica Ferreira, Sofia Pradhan, Pallab Penney, Mark Wang, Chunlei Liu, Wenhai Walseng, Even Mazor, Yariv MAbs Report Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities. Asymmetric monovalent bispecific IgGs (bsIgGs) have the additional advantage of maintaining a native antibody-like structure, which can provide favorable pharmacology and pharmacokinetic profiles. The production of correctly assembled asymmetric monovalent bsIgGs, however, is a complex engineering endeavor due to the propensity for non-cognate heavy and light chains to mis-pair. Previously, we introduced the DuetMab platform as a general solution for the production of bsIgGs, which utilizes an engineered interchain disulfide bond in one of the C(H)1-C(L) domains to promote orthogonal chain pairing between heavy and light chains. While highly effective in promoting cognate heavy and light chain pairing, residual chain mispairing could be detected for specific combinations of Fv pairs. Here, we present enhancements to the DuetMab design that improve chain pairing and production through the introduction of novel electrostatic steering mutations at the C(H)1-C(L) interface with lambda light chains (C(H)1-C(λ)). These mutations work together with previously established charge-pair mutations at the C(H)1-C(L) interface with kappa light chains (C(H)1-C(κ)) and Fab disulfide engineering to promote cognate heavy and light chain pairing and enable the reliable production of bsIgGs. Importantly, these enhanced DuetMabs do not require engineering of the variable domains and are robust when applied to a panel of bsIgGs with diverse Fv sequences. We present a comprehensive biochemical, biophysical, and functional characterization of the resulting DuetMabs to demonstrate compatibility with industrial production benchmarks. Overall, this enhanced DuetMab platform substantially streamlines process development of these disruptive biotherapeutics. Taylor & Francis 2023-11-06 /pmc/articles/PMC10629431/ /pubmed/37930310 http://dx.doi.org/10.1080/19420862.2023.2273449 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Report Bagert, John D. Oganesyan, Vaheh Chiang, Chi-I Iannotti, Mike Lin, Jia Yang, Chunning Payne, Sterling McMahon, Will Edwards, Samuel Dippel, Andrew Hutchinson, Mark Huang, Fengying Aleti, Vineela Niu, Chendi Qian, Chen Denham, Jessica Ferreira, Sofia Pradhan, Pallab Penney, Mark Wang, Chunlei Liu, Wenhai Walseng, Even Mazor, Yariv Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title | Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title_full | Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title_fullStr | Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title_full_unstemmed | Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title_short | Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the C(H)1-C(λ) interface |
title_sort | robust production of monovalent bispecific igg antibodies through novel electrostatic steering mutations at the c(h)1-c(λ) interface |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629431/ https://www.ncbi.nlm.nih.gov/pubmed/37930310 http://dx.doi.org/10.1080/19420862.2023.2273449 |
work_keys_str_mv | AT bagertjohnd robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT oganesyanvaheh robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT chiangchii robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT iannottimike robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT linjia robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT yangchunning robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT paynesterling robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT mcmahonwill robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT edwardssamuel robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT dippelandrew robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT hutchinsonmark robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT huangfengying robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT aletivineela robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT niuchendi robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT qianchen robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT denhamjessica robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT ferreirasofia robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT pradhanpallab robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT penneymark robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT wangchunlei robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT liuwenhai robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT walsengeven robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface AT mazoryariv robustproductionofmonovalentbispecificiggantibodiesthroughnovelelectrostaticsteeringmutationsatthech1clinterface |